Doubts over Medtronic's big China buy; Better defibrillator programming cuts down on risks;

 @FierceMedDev: BSX study shows improved defibrillator programming reduces unnecessary jolts as well as risk of death. More | Follow @FierceMedDev

 @MarkHFierce: BD ended its 2012 fiscal year on a down note. But CEO Forlenza qualifies it as a "solid finish." News | Follow @MarkHFierce

 @DamianFierce: Medical device manufacturer Onyx got snapped up for $43.25M by Sparton. Story | Follow @DamianFierce

> Improved defibrillator programming can reduce the risk of unnecessary shocks and death, a Boston Scientific ($BSX) and University of Rochester Medical Center study concludes. Release

> Bausch & Lomb has signed a deal to acquire the remaining shares of Technolas Perfect Vision, a joint venture that develops and sells cataract technologies. News

> Veredus Laboratories has launched the VereMTBTM, a multiplexed molecular diagnostic chip designed to detect Mycobacterium tuberculosis complex. More

> Medtronic ($MDT) has closed its $816 million deal for China's Kanghui Holdings, but some analysts warn that the deal may not be as promising as it sounds. Article

> Rochester Medical ($ROCM) saw its shares jump 1.2% after announcing it is getting out of the Foley catheter business. Story

> The medical device industry is likely mourning the electoral defeat of Republican U.S. Sen. Scott Brown, an outspoken device industry supporter, who lost to Harvard Law School Professor Elizabeth Warren in Tuesday's election. Story

> Edwards Lifesciences ($EW) disclosed that a federal probe into its Vigilance I heart monitor, which was recalled in 2006, has been ended. Story

Biotech News

 @FierceBiotech: Test could detect a range of cancers weeks before symptoms. More | Follow @FierceBiotech

 @JohnCFierce: Are clinical trial investigators guilty of mission creep? Report | Follow @JohnCFierce

 @RyanMFierce: Maverix enters genomics software game with Silicon Valley sizzle. More | Follow @RyanMFierce

> Roche, ImmunoGen gain speedy review for T-DM1 breast cancer breakthrough. News

> FDA hands Pfizer blockbuster approval for rheumatoid arthritis drug tofacitinib. Story

Pharma News

@FiercePharma: Are you ready, Humira? Pfizer nabs FDA blessing for blockbuster hopeful Xeljanz, for rheumatoid arthritis. Story | Follow @FiercePharma

> Roche's souped-up breast cancer drug steps on FDA fast track. Item

> Obama's re-elected. So what's next for pharma? Story

> Exec says GSK is back on the straight and narrow. Report

Drug Delivery News

> Hydrogel time bombs set off explosive drug release. Story

> Novartis submits COPD combination inhaler in Japan. Item

> $1M Gates Foundation grant to formulate lifesaving oxytocin. News

Biomarkers News

> Bowel cancer biomarkers from Down Under catch U.S. attention. Item

> Blood protein tags progression in ALS. Article

> Phase III finding points to masitinib CDx for pancreatic cancer. Story

> Breast cancer biomarkers predict tamoxifen response. Report

> Simple blood count points to survival in aggressive skin cancer. News

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.